{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:17:02Z","timestamp":1783027022206,"version":"3.54.6"},"reference-count":61,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aprim.2026.103518","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:15:07Z","timestamp":1781529307000},"page":"103518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Asistencia integral para mujeres con c\u00e1ncer de mama metast\u00e1sico y respuesta prolongada: opini\u00f3n de expertos sobre el tratamiento a largo plazo en Espa\u00f1a"],"prefix":"10.1016","volume":"58","author":[{"given":"Virginia","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Mart\u00ednez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Sanmart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan R.","family":"de la Haba-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Mart\u00ednez Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aprim.2026.103518_bib0310","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.aprim.2026.103518_bib0315","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1245\/s10434-021-10227-3","article-title":"Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients","volume":"28","author":"Taskindoust","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0320","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0325","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO2-04-01","article-title":"Abstract PO2-04-01: Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer","volume":"84","author":"Morganti","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.aprim.2026.103518_bib0330","article-title":"Major advancements in metastatic breast cancer treatment: When expanding options means prolonging survival","volume":"7","author":"Miglietta","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.aprim.2026.103518_bib0335","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/OP-24-00620","article-title":"Oncology and Primary Care Involvement in Breast Cancer Survivorship Care More Than 5 Years After Initial Treatment","volume":"21","author":"Radhakrishnan","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.aprim.2026.103518_bib0340","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/pcm-21-38","article-title":"Drug-related toxicity in breast cancer patients: A new path towards tailored treatment?.\u2014a narrative review","volume":"5","author":"Lai","year":"2022","journal-title":"Precis Cancer Med"},{"key":"10.1016\/j.aprim.2026.103518_bib0345","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-023-00776-9","article-title":"Mitigating long-term and delayed adverse events associated with cancer treatment: Implications for survivorship","volume":"20","author":"Lustberg","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0350","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12094-024-03571-9","article-title":"Spanish Society of Medical Oncology recommendations for comprehensive assessment and care of cancer survivors\u2019 needs","volume":"27","author":"Gallego","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0355","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2022.07.1941","article-title":"ESMO Expert Consensus Statements on Cancer Survivorship: Promoting high-quality survivorship care and research in Europe","volume":"33","author":"Vaz-Luis","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0360","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-025-01852-y","article-title":"Primary care providers and their needs caring for cancer survivors: A qualitative study","author":"Yi","year":"2025","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.aprim.2026.103518_bib0365","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10549-024-07524-2","article-title":"Real-world quality-of-life of patients with HR+\/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS","volume":"209","author":"Rocque","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.aprim.2026.103518_bib0370","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s41669-024-00478-7","article-title":"A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab","volume":"8","author":"Khoirunnisa","year":"2024","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.aprim.2026.103518_bib0375","first-page":"458","article-title":"Adherence to oral anticancer treatments: network and sentiment analysis exploring perceived internal and external determinants in patients with metastatic breast cancer","volume":"32","author":"Masiero","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.aprim.2026.103518_bib0380","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2147\/PPA.S224496","article-title":"Side Effects, Self-Management Activities, and Adherence to Oral Anticancer Agents","volume":"13","author":"Jiang","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.aprim.2026.103518_bib0385","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11764-017-0674-4","article-title":"Interventions to improve endocrine therapy adherence in breast cancer survivors: What is the evidence?","volume":"12","author":"Ekinci","year":"2018","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.aprim.2026.103518_bib0390","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.3390\/curroncol30040273","article-title":"The Relationship between Therapeutic Alliance and Quality of Care in Patients with Advanced Cancer in Spain","volume":"30","author":"Velasco-Dur\u00e1ntez","year":"2023","journal-title":"Current Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0395","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.537","article-title":"Patient-reported provider communication skills and adherence to recommended treatment in breast cancer","volume":"42","author":"Chino","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0400","first-page":"83","article-title":"Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence","volume":"11","author":"Gillespie","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0405","first-page":"279","article-title":"ONS GuidelinesTM to Support Patient Adherence to Oral Anticancer Medications","volume":"49","author":"Belcher","year":"2022","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.aprim.2026.103518_bib0410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21556660.2020.1857103","article-title":"Review of cyclin-dependent kinase 4\/6 inhibitors in the treatment of advanced or metastatic breast cancer","volume":"10","author":"Husinka","year":"2020","journal-title":"J Drug Assess"},{"key":"10.1016\/j.aprim.2026.103518_bib0415","unstructured":"Blasco A, Caballero C. Toxicidad de los tratamientos oncol\u00f3gicos. SEOM 2019 [consultado 22 Ago 2025] Disponible en: https:\/\/seom.org\/guia-actualizada-de-tratamientos\/toxicidad-de-los-tratamientos-oncologicos?showall=1&start=0"},{"key":"10.1016\/j.aprim.2026.103518_bib0420","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","article-title":"CDK4\/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety","volume":"50","author":"Wekking","year":"2023","journal-title":"Semin Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0425","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14740338.2024.2348566","article-title":"Hematological toxicity of cyclin-dependent kinase 4\/6 inhibitors in patients with breast cancer: A network meta-analysis and pharmacovigilance study","volume":"24","author":"Ding","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.aprim.2026.103518_bib0430","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3892\/ol.2024.14278","article-title":"Recommendations for cyclin\u2013dependent kinase 4\/6 inhibitor treatments in the context of co\u2013morbidity and drug interactions (Review)","volume":"27","author":"Teomete","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.aprim.2026.103518_bib0435","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(22)00242-2","article-title":"Management of common clinical problems experienced by survivors of cancer","volume":"399","author":"Emery","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.aprim.2026.103518_bib0440","article-title":"Long-Term Follow-Up Care After Treatment for Primary Breast Cancer: Strategies and Considerations","volume":"45","author":"Franzoi","year":"2025","journal-title":"Ame Soc Clini Oncol Educ Book"},{"key":"10.1016\/j.aprim.2026.103518_bib0445","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","article-title":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice","volume":"150","author":"Sibaud","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.aprim.2026.103518_bib0450","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0455","article-title":"Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer","volume":"28","author":"Li","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.aprim.2026.103518_bib0460","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/HCO.0000000000000637","article-title":"Cardiotoxicity of HER2-targeted therapies","volume":"34","author":"Copeland-Halperin","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.aprim.2026.103518_bib0465","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0470","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1378090","article-title":"CDK4\/6 inhibitors in drug-induced liver injury: A pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network","volume":"15","author":"She","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.aprim.2026.103518_bib0475","article-title":"Real-world pharmacovigilance assessment of hepatotoxicity risk with HER2-Targeted drugs using FAERS database analysis","volume":"15","author":"Dong","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.aprim.2026.103518_bib0480","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s11864-023-01137-5","article-title":"Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer","volume":"24","author":"Stanowicka-Grada","year":"2023","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0485","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(13)70076-7","article-title":"Incidence of unilateral arm lymphoedema after breast cancer: A systematic review and meta-analysis","volume":"14","author":"DiSipio","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0490","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1002\/cncr.34489","article-title":"Burden of lymphedema in long-term breast cancer survivors by race and age","volume":"128","author":"Ren","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.aprim.2026.103518_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-022-06850-7","article-title":"Bioimpedance spectroscopy for breast cancer-related lymphedema assessment: Clinical practice guidelines","volume":"198","author":"Shah","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.aprim.2026.103518_bib0500","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11096-010-9410-0","article-title":"Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs","volume":"32","author":"Voll","year":"2010","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.aprim.2026.103518_bib0505","first-page":"233","article-title":"Revisi\u00f3n de interacciones medicamentosas en tratamientos oncol\u00f3gicos ambulatorios desde un enfoque pr\u00e1ctico","volume":"34","author":"Vidal-L\u00f3pez","year":"2024","journal-title":"Rev a OFIL"},{"key":"10.1016\/j.aprim.2026.103518_bib0510","first-page":"21","article-title":"CDK4\/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions","author":"Roncato","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.aprim.2026.103518_bib0515","unstructured":"European Medicines Agency (EMA). Kisqali (Ribociblib) SUMMARY OF PRODUCT CHARACTERISTICS [consultado 15 Sep 2025] Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kisqali-epar-product-information_en.pdf"},{"key":"10.1016\/j.aprim.2026.103518_bib0520","first-page":"64","article-title":"QT STAR: Concomitant QTc-prolonging medication use among patients with HR+ \/ HER2\u2212 metastatic breast cancer receiving a CDK4\/6 inhibitor in first line","volume":"11","author":"Dent","year":"2025","journal-title":"Cardiooncology"},{"key":"10.1016\/j.aprim.2026.103518_bib0525","first-page":"7","article-title":"CARDIAC-STAR: Prevalence of cardiovascular comorbidities in patients with HR+ \/HER2\u2212 metastatic breast cancer","volume":"11","author":"Dent","year":"2025","journal-title":"Cardiooncology"},{"key":"10.1016\/j.aprim.2026.103518_bib0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: Practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"EclinicalMedicine"},{"key":"10.1016\/j.aprim.2026.103518_bib0535","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/ph18070959","article-title":"Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors","volume":"18","author":"Bud\u0103u","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.aprim.2026.103518_bib0540","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of Adults With Cancer: ASCO Guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aprim.2026.103518_bib0545","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/OP.20.00622","article-title":"Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase","volume":"17","author":"Kida","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.aprim.2026.103518_bib0550","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clbc.2019.11.004","article-title":"Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival","volume":"20","author":"Itani","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.aprim.2026.103518_bib0555","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2024.1403114","article-title":"Infographics on signs and symptoms of metastatic (secondary) breast cancer can empower women with a breast cancer diagnosis","volume":"15","author":"Derakshan","year":"2024","journal-title":"Front Psychol"},{"key":"10.1016\/j.aprim.2026.103518_bib0560","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11143992","article-title":"Living with Advanced Breast Cancer: A Descriptive Analysis of Survivorship Strategies","volume":"11","author":"Grimm","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.aprim.2026.103518_bib0565","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s13668-019-00278-0","article-title":"The Impact of Diet on Breast Cancer Outcomes","volume":"8","author":"Xu","year":"2019","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.aprim.2026.103518_bib0570","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ijc.35429","article-title":"Impact of exercise on sexual health, body image, and therapy-related symptoms in women with metastatic breast cancer: The randomized controlled PREFERABLE-EFFECT trial","volume":"157","author":"Schmidt","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.aprim.2026.103518_bib0575","doi-asserted-by":"crossref","DOI":"10.1177\/15347354221137285","article-title":"Yoga Therapy During Chemotherapy for Early-Stage and Locally Advanced Breast Cancer","volume":"21","author":"Greaney","year":"2022","journal-title":"Integr Cancer Ther"},{"key":"10.1016\/j.aprim.2026.103518_bib0580","doi-asserted-by":"crossref","DOI":"10.3389\/froh.2022.876941","article-title":"Dental Evaluation Prior to Cancer Therapy","volume":"3","author":"Yong","year":"2022","journal-title":"Front Oral Health"},{"key":"10.1016\/j.aprim.2026.103518_bib0585","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4143\/crt.2021.835","article-title":"Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors","volume":"54","author":"Tran","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.aprim.2026.103518_bib0590","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12912-023-01184-1","article-title":"Depression, anxiety and stress among metastatic breast cancer patients on chemotherapy in China","volume":"22","author":"Guo","year":"2023","journal-title":"BMC Nurs"},{"key":"10.1016\/j.aprim.2026.103518_bib0595","first-page":"289","article-title":"Recovering or working: women's experiences of working while coping with cancer: A qualitative study","volume":"33","author":"Gershfeld-Litvin","year":"2025","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.aprim.2026.103518_bib0600","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1080\/00224499.2014.928663","article-title":"Vaginal Dryness and Beyond: The Sexual Health Needs of Women Diagnosed With Metastatic Breast Cancer","volume":"52","author":"McClelland","year":"2015","journal-title":"J Sex Res"},{"key":"10.1016\/j.aprim.2026.103518_bib0605","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajog.2024.10.054","article-title":"Vaginal estrogen use in breast cancer survivors: A systematic review and meta-analysis of recurrence and mortality risks","volume":"232","author":"Beste","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.aprim.2026.103518_bib0610","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.864893","article-title":"Coping With Changes to Sex and Intimacy After a Diagnosis of Metastatic Breast Cancer: Results From a Qualitative Investigation With Patients and Partners","volume":"13","author":"Reese","year":"2022","journal-title":"Front Psychol"}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656726000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656726000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:28:28Z","timestamp":1783024108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656726000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0212656726000764"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2026.103518","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asistencia integral para mujeres con c\u00e1ncer de mama metast\u00e1sico y respuesta prolongada: opini\u00f3n de expertos sobre el tratamiento a largo plazo en Espa\u00f1a","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2026.103518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103518"}}